Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells

Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells

(2016) X. Niu et al.   CLINICAL CANCER RESEARCH

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Molecular Pathways: Targeting ATR in Cancer Therapy

(2015) L. M. Karnitz et al.   CLINICAL CANCER RESEARCH

Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase

(2015) Rémi Buisson et al.   MOLECULAR CELL

ATM and ATR as therapeutic targets in cancer

(2015) Anika Maria Weber et al.   PHARMACOLOGY & THERAPEUTICS

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

(2015) Amy B. Hall et al.   Oncotarget

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

(2014) L Molife et al.   Journal of Hematology & Oncology

Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199

(2014) X Niu et al.   LEUKEMIA

Causes and consequences of replication stress

(2013) Michelle K. Zeman et al.   NATURE CELL BIOLOGY

DNA Damage Sensing by the ATM and ATR Kinases

(2013) A. Marechal et al.   Cold Spring Harbor Perspectives in Biology

RNAi screening of the kinome with cytarabine in leukemias

(2012) R. Tibes et al.   BLOOD

A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3

(2012) Marshall A. Lichtman   BLOOD CELLS MOLECULES AND DISEASES

Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer

(2012) Guan Wang et al.   PLoS One

Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells

(2011) Xuelian Xu et al.   PLoS One

Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia

(2010) C. Xie et al.   CLINICAL CANCER RESEARCH

Histone  H2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

(2010) C. E. Redon et al.   CLINICAL CANCER RESEARCH

New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

(2010) Y. Dai et al.   CLINICAL CANCER RESEARCH

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

(2010) Jeffrey E Rubnitz et al.   LANCET ONCOLOGY

RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia

(2009) H. Edwards et al.   BLOOD

Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML

(2009) Kensuke Kojima et al.   CANCER SCIENCE

Targeting the DNA damage response for cancer therapy

(2009) Simon N. Powell et al.   DNA REPAIR

Implication of Checkpoint Kinase-dependent Up-regulation of Ribonucleotide Reductase R2 in DNA Damage Response

(2009) Yong-Wei Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY